Zdeněk Pospı́šil

Author

Zdeněk Pospı́šil

Also Known As

Pospíšil, Zdeněk, Z Pospisil, Z Pospišil, Z Pospísil, Z Pospísíl, Z Pospíšil, Z. POSPISIL, Z. POSPÍŠIL, Z. Pospisil, Z. Pospišil

193

Publications

990

Citations

H-Index

Concepts

All Affiliations

Masaryk University University Hospital Brno Institute of Haematology and Blood Transfusion Central European Institute of Technology – Masaryk University Central European Institute of Technology

About

Zdeněk Pospı́šil is an author at Masaryk University specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	187
2	Health Sciences	3	3	84
3	Natural Sciences	2	2	55
4	Language Studies	1	1	19
5	Public Health	1	1	21

Zdeněk Pospı́šil

Publications

406

Citations

H-Index

Page 1

	Year	Citations
Seroprevalence of H1N1, H3N2 and H1N2 influenza viruses in pigs in seven European countries in 2002–2003 Kristien Van Reeth, Ian H. Brown, Ralf Dürrwald, Influenza and Other Respiratory Viruses	2008	111
Comparison of antibacterial effect of seven 1-monoglycerides on food-borne pathogens or spoilage bacteria Leona Buňková, František Buňka, Rahula Janiš, Acta Veterinaria Brno Food-borne PathogensLipid AnalysisSpoilage BacteriaProbioticFatty Acids	2011	36
Restriction fragment length polymorphism and virulence of Czech Toxoplasma gondii strains Ivan Literák, Ivan Rychlı́k, V. Svobodová, International Journal for Parasitology BiologyParasitic ProtozoaNatural SciencesGeneticsPathogenesis	1998	34
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression Michael Doubek, Ivo Palásek, Zdeněk Pospı́šil, Experimental Hematology Hematological MalignancyMolecular RelapseMolecular MarkersMedicineAcute Myeloid Leukemia	2009	32
Symptomatic Intravenous Antipyretic Therapy Andrea Obořilová, Jiřı́ Mayer, Zdeněk Pospı́šil, Journal of Pain and Symptom Management ThrombosisPharmacotherapyMedicineAnticoagulantAdverse Drug Reaction	2002	24
Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis Kateřina Machová Poláková, Václava Polívková, Jana Rulcová, Experimental Hematology Hematological MalignancyOncologyMedicineGeneticsMutation Analysis	2009	22
Phytophagous and predatory mites (Acari: Tetranychidae, Eriophyidae, Phytoseiidae, Stigmaeidae) in South Moravian vineyards, Czechoslovakia, treated with various types of chemicals M. Hluchý, Zdeněk Pospı́šil, Miloslav Zacharda Experimental and Applied Acarology BiologyTerrestrial ArthropodBotanyPlant-insect InteractionNatural Sciences	1991	21
Ptolemaic military operations were a dominant factor in the spread of Egyptian cults across the early Hellenistic Aegean Sea Tomáš Glomb, Adam Mertel, Zdeněk Pospı́šil, PLoS ONE Ancient Egyptian ReligionPtolemaic Military OperationsHistory Of ScienceHistorical ArchaeologyEarly Spread	2018	19
Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice Michael Doubek, Petra Obrtlíková, Lukáš Smolej, European Journal Of Haematology	2011	18
Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? Daniela Žáčková, Hana Klamová, Ladislav Dušek, American Journal of Hematology Chronic PhaseHematological MalignancyChronic Myeloid LeukemiaOncologyReal Life Data	2010	16

Page 1